Search Results for “immune” – Page 66 – media

Odds of Heart Attack Six Times Higher With Flu Diagnosis

Marcia Frellick April 17, 2023 People diagnosed with influenza are six times more likely to have a heart attack within the first week that they test positive for the influenza virus than they are in the year before or the year after, a new study indicates. This work, led by Annemarijn de Boer, PhD, with the Julius Center for Life Sciences and Primary Care, UMC Utrecht in Utrecht, the Netherlands, comes 5 years after a 2018 study by Canadian researchers found a similar strong connection between flu and heart attack in people hospitalized for heart attacks. Annemarijn de Boer, PhD The current findings will be presented by de Boer at the at this year’s European Congress of Clinical Microbiology & Infectious Diseases in Copenhagen, Denmark, on April 18. de Boer’s team explains that the connection between influenza and heart attack lies in the influenza virus’s ability to increase the stickiness or clotting of blood. ...
- Source: drugdu
- 123
- April 19, 2023
Pre- and post-surgical immunotherapy-based treatment significantly improved lung cancer outcomes

Reviewed by Emily Henderson, B.Sc.Apr 17 2023 A regimen of pre-surgical immunotherapy and chemotherapy followed by post-surgical immunotherapy significantly improved event-free survival (EFS) and pathologic complete response (pCR) rates compared to chemotherapy alone for patients with operable non-small cell lung cancer (NSCLC), according to Phase III trial results presented today by researchers from The University of Texas MD Anderson Cancer Center at the American Association for Cancer Research (AACR) Annual Meeting 2023. The AEGEAN trial evaluated durvalumab given perioperatively, meaning therapy is given both before and after surgery. Participants on the trial received either pre-surgical (neoadjuvant) durvalumab and platinum-based chemotherapy followed by post-surgical (adjuvant) durvalumab or neoadjuvant placebo and chemotherapy followed by adjuvant placebo. These represent the first data presented on the benefits of perioperative immunotherapy for resectable NSCLC and adds to the growing evidence supporting the benefits of both neoadjuvant and adjuvant immunotherapy for these patients. Our goal is to increase cures for lung cancer. ...
- Source: drugdu
- 124
- April 18, 2023
Adding new vaccine type to leading immunotherapy dramatically reduced melanoma recurrence

The combination of an experimental mRNA vaccine with an immunotherapy reduced the likelihood of melanoma recurring or causing death by 44% when compared to immunotherapy alone, a new clinical trial shows. Led by researchers at NYU Langone Health and its Perlmutter Cancer Center, the randomized phase 2b trial involved men and women who had surgery to remove melanoma from lymph nodes or other organs and were at high risk of the disease returning in sites distant from the original cancer. Among 107 study subjects who were injected with both the experimental vaccine, called mRNA-4157/V940, and the immunotherapy pembrolizumab, the cancer returned in 24 subjects (22.4%) within two years of follow-up, compared with 20 out of 50 (40%) who received only pembrolizumab. “Our phase 2b study shows that a neoantigen mRNA vaccine, when used in combination with pembrolizumab, resulted in prolonged time without recurrence or death compared with pembrolizumab alone,” said study senior investigator ...
- Source: drugdu
- 230
- April 17, 2023
FDA, citing safety concerns, places partial hold on Merck KGaA’s MS drug

Dive Brief: The Food and Drug Administration told Merck KGaA not to give an experimental drug for multiple sclerosis to new patients and to pause treatment for study participants who have been on it for less than 70 days amid concerns about possible liver damage. Regulators acted after laboratory tests suggested the livers of two patients might have been adversely affected by the drug, known as evobrutinib. However, neither patient exhibited symptoms and their liver enzyme levels returned to normal after they stopped taking the medicine, Merck KGaA said Wednesday. The German drugmaker had already fully enrolled a Phase 3 study known as Evolution, and that program will continue as planned because all the patients have already had received the medication for at least 70 days. Results are still expected in the fourth quarter. Dive Insight: Evobrutinib is part of a class of drugs known as BTK ...
- Source: drugdu
- 200
- April 13, 2023
The virological characteristics of XBB.1.16

In a recent study posted to the bioRxiv* preprint server, researchers perform extensive multiscale investigations to explore virological characteristics of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron XBB subvariant, XBB.1.16. Background The SARS-CoV-2 XBB.1.16 variant is associated with a 1.27- and 1.17-fold higher effective reproductive number (Re) as compared to the XBB.1 and XBB.1.5 subvariants, respectively, thus indicating the ability of this novel Omicron variant to disseminate quickly. As a result of this increased transmissibility, the World Health Organization (WHO) began monitoring XBB.1.16 on March 30, 2023, following its detection in several countries, including India. Earlier, the SARS-CoV-2 Omicron XBB subvariants with the F486P substitution in their spike (S) protein, which include XBB.1.5 and XBB.1.9, were widely circulating worldwide. Study findings The current analyses showed that as compared to its predecessor mutant strains, XBB.1.16 had two S substitutions, including E180V and T478R in the N-terminal domain (NTD) ...
- Source: drugdu
- 120
- April 13, 2023
‘This Is a First’

Marcia Frellick April 07, 2023 Editor’s note: Find the latest COVID-19 news and guidance in Medscape’s Coronavirus Resource Center. Researchers have found for the first time that COVID infection has crossed the placenta and caused brain damage in two newborns, according to a study published online today in Pediatrics. One of the infants died at 13 months and the other remained in hospice care at time of manuscript submission. Lead author Merline Benny, MD, with the division of neonatology, department of pediatrics at University of Miami, and colleagues briefed reporters today ahead of the release. “This is a first,” said senior author Shahnaz Duara, MD, medical director of the Neonatal Intensive Care Unit at Holtz Children’s Hospital, Miami, explaining it is the first study to confirm cross-placental SARS-CoV-2 transmission leading to brain injury in a newborn. Both infants negative for the virus at birth ...
- Source: drugdu
- 150
- April 12, 2023
Moderna cancer vaccine takes positive step

Company’s candidate, in combination with MSD’s Keytruda, receives PRIME designation Moderna has announced that mRNA-4157/V940 – its investigational cancer vaccine – in combination with Keytruda, Merck’s anti-PD-1 therapy, has been granted Priority Medicines (PRIME) scheme designation by the European Medicines Agency (EMA). It concerns the adjuvant treatment of patients with high-risk stage III/IV melanoma following complete resection. The vaccine mRNA-4157/V940 stimulates an immune response by generating specific T cell responses based on the unique mutational signature of a patient’s tumour. The EMA awarded the PRIME scheme designation following positive data emerging from the phase 2b KEYNOTE-942/mRNA-4157-P201 clinical trial. The results from this research will be shared at the American Association for Cancer Research (AACR) in mid-April. PRIME is a regulatory system run by the EMA that provides support for the development of medicines that target unmet medical needs. Through PRIME, the EMA offers proactive and early ...
- Source: drugdu
- 112
- April 12, 2023
Pfizer and Moderna’s COVID-19 vaccines offer lasting protection

Study finds on April 7th, 2023, Pharmaceutical Technology reported that a new study has found that Pfizer and Moderna’s COVID-19 vaccines offer lasting protection against the virus. The study, which was published in the New England Journal of Medicine, found that people who received either vaccine had robust and persistent antibody and T cell responses against SARS-CoV-2, the virus that causes COVID-19, even six months after receiving the second dose. The study followed 2,500 healthcare workers who received either the Pfizer or Moderna vaccine and found that their immune responses remained strong over time. The researchers noted that while antibody levels did decline over time, the levels were still high enough to provide protection against the virus. The findings are significant because they suggest that the vaccines are likely to provide long-term protection against COVID-19. The study also provides reassurance that the vaccines are effective against new variants of ...
- Source: drugdu
- 175
- April 12, 2023
New study shows SARS-CoV-2 infection accelerates the progression of dementia

The possible common pathomechanisms linking multiple sclerosis and post-COVID-19 brain involvement (A). Proposal of a new codename regarding post-COVID-19 cognitive sequelae (B). Credit: Journal of Alzheimer’s Disease Reports (2023). DOI: 10.3233/ADR-220090 Infection with SARS-CoV-2 has a significant impact on cognitive function in patients with preexisting dementia, according to new research published in the Journal of Alzheimer’s Disease Reports. Patients with all subtypes of dementia included in the study experienced rapidly progressive dementia following infection with SARS-CoV-2. Since the first wave of COVID-19, neurologists have noticed both acute and long-term neurological syndromes and neuropsychiatric sequelae of this infectious disease. Insights into the impact of COVID-19 on human cognition has so far remained unclear, with neurologists referring to “brain fog.” A group of researchers driven to gain a better understanding of and dissipate this fog investigated the effects of COVID-19 on cognitive impairment in 14 patients with preexisting dementia (four with Alzheimer’s disease [AD], five with vascular dementia, three ...
- Source: drugdu
- 164
- April 7, 2023
Immunomodulators boost vaccine response and reduce inflammation, finds study

Adjuvants—ingredients that help boost the immune response in vaccines—have been used in vaccines for decades. But inducing a stronger immune response can result in more unwanted side effects, like swelling at the injection site or fever and body aches. Researchers at the Pritzker School of Molecular Engineering (PME) at the University of Chicago have found that adding small molecules called immunomodulators to vaccine adjuvants gives them the ability to better regulate the body’s response to vaccines. “If you think of adjuvants as a megaphone that stimulates the immune system, then you can think of immunomodulators as a sound mixer,” said Jeremiah Kim, a graduate student and co-lead author of the paper. “We’re able to selectively tune the immune response to reduce negative side effects.” In models, adding immunomodulators to a flu vaccine increased antibody response, and adding them to a typhoid vaccine reduced inflammation. The results were published in ACS Central Science. Graduate student Matthew Rosenberger was also a ...
- Source: drugdu
- 150
- April 6, 2023

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.